Advancing and Translating Knowledge in Vascular Medicine by Marc Husmann & Matthias Barton
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
published: 29 October 2014
doi: 10.3389/fcvm.2014.00006
Advancing and translating knowledge in vascular medicine
Marc Husmann1*† and Matthias Barton2*†‡
1 Clinic of Angiology, University Hospital Zürich, Zürich, Switzerland
2 Molecular Internal Medicine, University of Zürich, Zürich, Switzerland
Edited and reviewed by:
SimonW. Rabkin, University of British
Columbia, Canada
*Correspondence:
Marc Husmann, M.D., Clinic of
Angiology, University Hospital Zürich,
Rämisstrasse 100, Zürich CH-8091,
Switzerland
e-mail: marc.husmann@usz.ch;
Matthias Barton, M.D., University of
Zürich, Y44 G22,Winterthurerstrasse
190, Zürich CH-8057, Switzerland
e-mail: barton@access.uzh.ch
†Chief Editor, Frontiers in
Cardiovascular Medicine – Vascular
Medicine
‡Editor-in-Chief, Frontiers in
Cardiovascular Medicine
For centuries, physicians have depended on the use of written information to gain knowl-
edge. Book printing and binding introduced by Gutenberg in the fifteenth century revo-
lutionized and accelerated the distribution of information. Advancing medical knowledge
and progress is not only linked to the scientific quality of a discovery determining it will
be accepted by the peers but also by its communication and sharing of new findings with
the medical community. All these factors determine whether new knowledge will advance
and improve clinical practice, medical education, and ultimately, patient care, and human
health. In the past decade medical publishing has witnessed a revolution with regard to the
instant, online availability of published “open access” information, which can be accessed
and printed from any computer connected to the internet. As an example, how language
and availability of printed information may affect distribution of knowledge, we discuss the
publication of the first results of balloon angioplasty in patients with peripheral vascular
disease 40 years ago by Andreas Grüntzig, M.D. at the University of Zürich. Vascular Med-
icine, as part of Frontiers in Cardiovascular Medicine, will provide open access provided
to all published content for sharing and distributing new and most up-to-date information
on clinical practice and medical knowledge in vascular medicine. We anticipate that the
ongoing transformation of scientific publishing through open access will further accelerate
this process and make new knowledge available even faster. Immediate, unrestricted, and
rapid access to the most current knowledge published will play a role in maintaining and
advancing human vascular health across the globe.
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INTRODUCTION: COMMUNICATION IN MEDICINE
For centuries, physicians have depended on the use of written
information to gain knowledge and the first known examples
were written on clay or papyrus. Book printing and binding –
introduced by Gutenberg in the 15th century – revolutionized
and accelerated the distribution of information. The first medical
journals were launched already in the eighteenth century (1–4)
and by the middle of the nineteenth century “if you were a scien-
tist you were expected to read French, English, and German” (5). At
the time, the German language was considered the primary lan-
guage of international scientific communication because German
scientists held the leading position in many disciplines, including
chemistry, mathematics, and physics (6). In the nineteenth century
and early twentieth century, German was also the language of sci-
entific publication in Vienna, then the reputed center of medicine,
psychology, and psychiatry, as well as in Czechoslovakia, Poland,
Scandinavia, and the Netherlands (6). Even in English-speaking
countries such as the UK and the United States, scientists were
expected to read German to keep up with the developments in
their fields (6, 7). After the Nazi regime came into power in 1933,
German successively lost its predominance as a scientific language,
scientists – who had left Germany and took exile in the United
States or the UK – started publishing their work in English (6, 8).
However, not until 1960 English fully took over as the primary
language of science (9). In fact, many German medical journals
with a long-publishing tradition successively changed to publish
in English to increase the global visibility of their articles published
(9). Today, more than 98% of all scientific articles published are
published in English (8).
COMMUNICATING PROGRESS IN MEDICINE
Communication of scientific discoveries and medical progress is
directly linked to population health. In that context, translational
medicine is concerned with the translation of research discov-
eries into clinical application for the prevention, diagnosis, and
treatment of human diseases. On February 12, 1974, when at the
University of Zürich German physician Andreas Grüntzig, M.D.
(1939–1985, Figure 1), for the first time applied a balloon-tipped
dilating catheter to treat a patient with peripheral vascular disease
(10, 11), he could not know that 40 years later his method would
be considered as one of the most important therapeutic advances
and outstanding examples of translational medicine of the twen-
tieth century (12). Though was a major breakthrough for vascular
medicine, and Grüntzig and his colleague, chemist Heinrich Hopff
(with whom he had developed the new polyvinyl chloride (PVC)
balloon device (10)), wanted to publish both the balloon catheter
concept and the first patient cases treated with this new method.
This was at a time when the first Xerox machines had arrived in
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FIGURE 1 | Andreas Grüntzig, M.D. (1939–1985), photograph taken
1982 in Nürnberg, Germany. Photograph courtesy of Felix Mahler, M.D.,
and used with his permission.
offices just a few years before, when there were no computers, cal-
culators, or an internet; at a time when statistical analysis had to
be done without the help of statistics computer programs, when
scientific manuscripts and their carbon copies had be written on
a typewriter, and when figures had to be hand-drawn with rulers
and black ink.
For the publication of their findings Grüntzig and Hopff chose
a journal that only published articles in German (10). Automat-
ically, this meant that access to this new medical information
was going to be neither rapid nor global. In fact, access to the
new information was delayed by the printing process which in
those days could require several months up to 2 years. The latter
happened to one of the research groups who independently dis-
covered the vascular activity of an endothelium-derived peptide
(13), which was later identified as endothelin (14). Moreover, the
publication by Grüntzig and Hopff could be read only by those
individuals proficient in the German language, and was restricted
to German-speaking countries in which printed journal copies
were distributed among its subscribers. Fortunately, the article
did contain an English abstract (Figure 2). In October of 1977,
Grüntzig went global with his intellectual property by filing a
patent application for the balloon angioplasty device in Switzer-
land,Germany,France, the United Kingdom,the United States, and
Japan (15). However, this patent was not issued until 1980, 6 years
after Grüntzig had begun treating patients using his new method.
Regardless of the patent being issued, it took a full 5 years until
Grüntzig’s new balloon angioplasty method finally reached the
United States (16). The restriction of dissemination of Grüntzig’s
new treatment of peripheral vascular disease within the medical
community can serve as a good example of how access to impor-
tant new medical information can be delayed namely by limiting
the communication required for the attention an information may
deserve. Ironically, the journal originally chosen by Grüntzig and
Hopff in 1974 to publish his first balloon angioplasty cases even
today still publishes most of its articles in German; however, it may
occasionally consider manuscripts written in English.
OPEN ACCESS TO KNOWLEDGE IN VASCULAR MEDICINE
Advancing medical knowledge and progress is not only linked
to the scientific quality of a discovery, which will determine its
acceptance by the peers, but also by its communication and shar-
ing of new findings with the medical community. All these fac-
tors determine whether new knowledge will be able to advance
and improve clinical practice, medical education, and ultimately,
patient care and human health. Medical publishing has recently
witnessed a revolution through open access publishing and the
online availability of published information, which can be accessed
and printed instantaneously from any computer connected to the
internet. The advantages of such a development have been realized
more than a decade ago (17) and are obvious: articles published
“open access” allow physicians to retrieve the most current infor-
mation instantaneously without delay, utilize said information for
clinical decision making, teaching of medical students and fel-
lows. Finally, physicians and medical scientists can use open access
journals to communicate their own research or to share clinical
knowledge with their colleagues.
Printed medical journals and text books by nature have a lim-
ited number of printed pages. This limitation, which is simply
due to economic reasons and costs, often prevents important and
noteworthy articles to be published in widely read journals. In fact,
due to the printed pages limit many journals in medicine or sci-
ence can accept only 20% or less of all manuscripts submitted. As a
result, many otherwise fine articles are published with considerable
delay or sometimes cannot even be published at all in a particular
journal. Unfortunately, this also slows down advancement of med-
ical progress and understanding of new scientific questions being
addressed in a manuscript. Some scientists in the field have even
abandoned submitting manuscripts to some of the key journals, as
they feel that the way by which these journals handle manuscript
submissions distorts the scientific process (18, 19).
A NEW ERA FOR VASCULAR MEDICINE
The key element of quality control in medical and scientific pub-
lishing always has been and will remain high-level, independent
peer-review of studies by experts knowledgeable in a particular
field, regardless whether a manuscript contains data or content
related to medicine or science. In most of today’s medical jour-
nals, authors do not learn about the identity of those who review
or reviewed a particular manuscript. Sometimes, they can be direct
competitors, working in the same area, which may go unnoticed
by the Editors. In addition, reviewers normally report their man-
uscript assessments to the editors who will then make a decision
about the fate of the manuscript which will then be communicated
to the corresponding author. While there is no need to criticize
this approach, it often does lead to a considerable delay until a
final decision can be reached, particularly, when several revisions
of a manuscript are required. What is and will remain important,
though is the independence and the high scientific expertise of any
editor or reviewer assessing a manuscript submitted for review.
As with all Frontiers journals, we are taking the same new
approach with Vascular Medicine to increase transparency of the
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FIGURE 2 | First page of the original article published in 1974 in German
by Andreas Grüntzig, M.D. and Heinrich Hopff, Ph.D., reporting Grüntzig’s
the new method of balloon angioplasty and results of the first 15
patients with peripheral artery disease successfully treated with this
new therapy. Note the insert of an English abstract on the right of the page.
Reproduced from Grüntzig and Hopff (10), with permission of the publisher.
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FIGURE 3 | Supplemental information (“Zur Arbeit Grüntzig, Hopff”)
to the article depicted in Figure 2, showing arterial angiograms of
two patients with peripheral artery disease before (left), during
(middle), and after (right) percutaneous balloon angioplasty
performed by Andreas Grüntzig, M.D. The first angiogram in panel 1
(Abb. 1) indicates left superficial femoral artery stenosis in a 71-year-old
man, the procedure was performed on April 9, 1974. The left angiogram
panel 2 (Abb. 2) indicates a high-grade stenosis of the left common iliac
artery in a 73-year-old male patient, the procedure was performed on
March 6, 1974. Note the differently sized angioplasty balloons, both in
diameter and length. The German figure legend indicates that both
patients were free of symptoms on follow-up 3 months after the
procedure. Reproduced from Grüntzig and Hopff (10), with permission of
the publisher.
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review and decision processes and to shorten the review process
while maintaining a high quality of the scientific peer-review.
Implementing the Frontiers interactive review, authors are
required to directly interact with reviewers and the Editor after the
manuscript has been submitted. This approach not only dramat-
ically shortens the time required to address issues raised by the
reviewers but also allows authors to directly communicate with
their reviewers who at that stage remain anonymous. Only after
the paper has been accepted for publication authors will learn the
identity of their reviewers, and names and affiliations will be listed
on the published manuscript.
A NEW JOURNAL: GOALS AND EXPECTATIONS
We anticipate and hope that Vascular Medicine will develop into an
open access knowledge platform with a strong clinical focus allow-
ing physicians, health professionals, and vascular disease specialists
to obtain and communicate information relevant to teaching and
practicing vascular medicine. Readers and authors will have access
to information on atherosclerotic vascular disease affecting the
aorta and peripheral, renovisceral, and extracranial arteries, as well
as related clinical complications such as acute and chronic critical
limb ischemia and arterial aneurysms. Moreover, the journal offers
articles on medical and interventional treatment of vascular dis-
eases, particularly, studies on endovascular surgery and vascular
interventions (20). In addition to atherosclerotic vascular disease,
one of the main areas in vascular medicine, the Journal also covers
other kinds of vascular diseases involving the macro- or microcir-
culation, vascular malformations, venous disease, and lymphatic
diseases (21). The Journal will also feature articles on primary
and secondary vascular disease prevention (22–24), new therapies
(25–27), translational medicine (28), and medical education in the
field of vascular medicine.
Although Vascular Medicine is primarily focusing on clinical
medicine, human trials, and translational clinical research (12,
29), manuscripts reporting results from preclinical and exper-
imental studies will be considered as long they are related to
vascular disease and advance the understanding of the patho-
physiology of the related disease condition or help to develop
new treatments (28). Articles made available in Vascular Medi-
cine are meant to continuously increase insights in the under-
standing of disease and treatment and to foster medical educa-
tion – all to advance clinical practice and patient care in vascular
medicine.
Forty years ago the vascular medicine pioneer Andreas
Grüntzig, M.D., at our institution published the first results of
balloon angioplasty treatment of patients with peripheral vas-
cular disease (Figure 3) in a journal that was only available
in German-speaking countries and to readers proficient in the
German language (10). Times have changed. As the Editors of
Vascular Medicine, we are confident that open access provided to
its content published in today’s global language of science (8) will
advance communication and distribution of new and most up-to-
date information on clinical practice and medical knowledge in
vascular medicine (17, 30). We anticipate that the ongoing trans-
formation of scientific publishing through open access – which
Frontiers in Cardiovascular Medicine has become part of – will
further accelerate this process to make new information available
even faster. Immediate, unrestricted, and free global access to the
most current published knowledge will play a role in maintaining
and advancing human vascular health.
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